Product Pipeline

SuviCa’s Pipeline.

Currently, SuviCa has a small molecule protein synthesis inhibitor in pre-clinical development.

SVC112 – With a patent filed for Composition of Matter protection, SVC112 has shown pre-clinical efficacy as monotherapy and in combination with standard therapies such as radiation and newly approved targeted agents. SVC112 is in pre-clinical development for a variety of cancer indications, including head & neck cancer, melanoma, colorectal cancer, and non-small cell lung cancer.